CLL-IPI Validated and Compared With MDACC Index in Newly Diagnosed Patients

Share this content:
The chronic lymphocytic leukemia international prognostic index (CLL-IPI) was recently developed using data from approximately 3500 patients.
The chronic lymphocytic leukemia international prognostic index (CLL-IPI) was recently developed using data from approximately 3500 patients.

The chronic lymphocytic leukemia international prognostic index (CLL-IPI) was recently developed for the prediction of overall survival, using data from approximately 3500 patients. The CLL-IPI can also predict time-to-first treatment failure in patients with newly diagnosed disease.

In a letter published in Blood, researchers in Italy describe how they evaluated the validity and reproducibility of the CLL-IPI in an independent cohort of 1364 newly diagnosed and non-referred patients.1

According to the CLL-IPI, 471 patients were classified as low-risk, 214 as intermediate-risk, 139 as high-risk, and 34 as very high-risk, with stratification demonstrated significant differences in overall survival among the prognostic groups.

Median 5-year and 10-year overall survival rates by CLL-IPI category were similar to those originally observed in the initial Mayo Clinic study, suggesting that survival estimates provided by the CLL-IPI are reproducible.

RELATED: Ofatumumab Active for Induction and Maintenance in Untreated CLL

The researchers compared the CLL-IPI with MDACC index score for predicting overall survival and time-to-first treatment failure in newly diagnosed patients.

The CLL-IPI has higher prognostic accuracy for predicting overall survival than the MDACC index score, and the CLL-IPI appeared to better predict progression than the MDACC score.                                

Reference

  1. Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index: Analysis of 1364 newly diagnosed patients. Blood. 2016 Aug 22. doi: 10.1182/blood-2016-07-728261 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs